Umoja Biopharma key facts
as of Oct 2026- Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells.
- Umoja Biopharma is valued at approximately $508.8M as of Oct 2026, up 21% since its later-stage round, Jan 2025, per PrivateMarketView’s mark.
- It has raised $371.0M across 1 recorded rounds; the latest was Later Stage VC ($210.0M) in Jun 2021.
- Notable investors include SoftBank Investment Advisers, Qiming Venture Partners USA, Temasek Holdings, Realm Capital Ventures, Alexandria Venture Investments — 25 tracked in total.
- 1 institutional filer reports fund marks on Umoja Biopharma across 6 filings.
- Umoja Biopharma has filed 1 Form D with the SEC, most recently Jun 2021 ($210.0M sold to 29 investors).
- Status: Privately Held (backing).
Up 21% since its later-stage round, Jan 2025 ($420.0M post-money).
- ·The complete investor list: 25 names
- ·Watch Umoja Biopharma: the Monday email on marks, rounds and moves
Institutional fund marks on Umoja Biopharma
1 filers · latest Jul 20261 SEC-registered fund reported 6 fair-value marks on Umoja Biopharma between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Umoja Biopharma funding rounds
1 roundsWho backs Umoja Biopharma
25+Umoja Biopharma valuation
Umoja Biopharma is valued at approximately $509 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Jan 2025, at a $420 million post-money valuation; the current figure is up 21% since.
Recent activity
In the last 90 days, Umoja Biopharma's record added 1 institutional fund mark (latest period Jul 2026).
How much has Umoja Biopharma raised?
Umoja Biopharma has raised $371 million in total; 1 of its rounds is on record. The largest on record was a $210 million later-stage round in Jun 2021.
Umoja Biopharma has filed 1 Form D with the SEC, most recently in Jun 2021 ($210 million sold to 29 investors).
Institutional holders and vehicles
1 SEC-registered fund reported 6 fair-value marks on Umoja Biopharma between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Umoja Biopharma investors
25 investors are on record for Umoja Biopharma, including SoftBank Investment Advisers, Qiming Venture Partners USA, Temasek Holdings and Realm Capital Ventures. By type, the record holds 7 venture capital firms and 3 hedge funds. The later-stage round in Jun 2021 drew 29 investors.
About Umoja Biopharma
Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. The company's platform offers integrated gene delivery technology, in-house lentiviral vector development, and a pipeline of in vivo cell therapies, enabling clinical researchers to pursue treatments that may reach more patients with improved accessibility and immune system-based control compared to conventional methods.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2019
- Employees
- 195
- Website
- umoja-biopharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.